CN112752838A - 制备引入外源抗原受体的细胞的方法 - Google Patents

制备引入外源抗原受体的细胞的方法 Download PDF

Info

Publication number
CN112752838A
CN112752838A CN201980062820.4A CN201980062820A CN112752838A CN 112752838 A CN112752838 A CN 112752838A CN 201980062820 A CN201980062820 A CN 201980062820A CN 112752838 A CN112752838 A CN 112752838A
Authority
CN
China
Prior art keywords
tcr
gene
cells
cell
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980062820.4A
Other languages
English (en)
Chinese (zh)
Inventor
河本宏
县保年
永野诚治
寺田晃士
增田乔子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiga University of Medical Science NUC
Kyoto University NUC
Original Assignee
Shiga University of Medical Science NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiga University of Medical Science NUC, Kyoto University NUC filed Critical Shiga University of Medical Science NUC
Publication of CN112752838A publication Critical patent/CN112752838A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
CN201980062820.4A 2018-07-26 2019-07-26 制备引入外源抗原受体的细胞的方法 Pending CN112752838A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-140523 2018-07-26
JP2018140523 2018-07-26
PCT/JP2019/029537 WO2020022512A1 (ja) 2018-07-26 2019-07-26 外来抗原レセプター遺伝子導入細胞の製造方法

Publications (1)

Publication Number Publication Date
CN112752838A true CN112752838A (zh) 2021-05-04

Family

ID=69180441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980062820.4A Pending CN112752838A (zh) 2018-07-26 2019-07-26 制备引入外源抗原受体的细胞的方法

Country Status (7)

Country Link
US (1) US20210381008A1 (https=)
EP (1) EP3845638A4 (https=)
JP (1) JP7422365B2 (https=)
CN (1) CN112752838A (https=)
AU (1) AU2019312008B2 (https=)
SG (1) SG11202101789SA (https=)
WO (1) WO2020022512A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
WO2022059780A1 (ja) * 2020-09-18 2022-03-24 サイアス株式会社 ｉＰＳ細胞を介する再生Ｔ細胞の製造方法
CA3193384A1 (en) 2020-09-24 2022-03-31 Hiroshi Kawamoto Method for preparing effector cells with desired specificity
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
JPWO2022220146A1 (https=) * 2021-04-16 2022-10-20
US20250163475A1 (en) * 2021-12-27 2025-05-22 Gracell Biotechnologies (Shanghai) Co., Ltd. Systems and methods for cell modification
KR20260047608A (ko) * 2023-08-04 2026-04-08 갓코호우징 도쿄리카다이가쿠 면역 세포의 제조 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079673A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CN107002036A (zh) * 2014-07-18 2017-08-01 河本宏 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法
WO2017180989A2 (en) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
JPWO2011096482A1 (ja) 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
LT3424947T (lt) * 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
AU2014248119B2 (en) 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
WO2016010155A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
JPWO2016010153A1 (ja) * 2014-07-18 2017-04-27 宏 河本 免疫細胞療法用ｔ細胞の誘導方法
CN105316362B (zh) 2015-08-19 2020-03-17 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
ES2886631T3 (es) 2016-04-15 2021-12-20 Univ Kyoto Método para inducir células T positivas para CD8 específicas de antígeno

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002036A (zh) * 2014-07-18 2017-08-01 河本宏 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法
WO2017079673A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
WO2017180989A2 (en) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TAKUYA MAEDA ET AL.: "Regeneration of tumor-antigen-specific cytotoxic T lymphocytes from ipscs transduced with exogenous tcr genes", 《MOLECULAR THERAPY》, vol. 19, pages 250 - 260, XP055905953, DOI: 10.1016/j.omtm.2020.09.011 *
毕爱华等: "《医学免疫学》", vol. 1, 31 July 1995, 人民军医出版社, pages: 167 - 168 *
龚英等: "Dual-RMCE介导的T细胞受体基因置换系统的建立", 《中国细胞生物学学报》, vol. 37, no. 11, pages 1481 *

Also Published As

Publication number Publication date
EP3845638A1 (en) 2021-07-07
JP7422365B2 (ja) 2024-01-26
EP3845638A4 (en) 2022-05-11
AU2019312008A1 (en) 2021-03-18
WO2020022512A1 (ja) 2020-01-30
US20210381008A1 (en) 2021-12-09
JPWO2020022512A1 (ja) 2021-08-02
SG11202101789SA (en) 2021-03-30
AU2019312008B2 (en) 2026-04-23

Similar Documents

Publication Publication Date Title
CN112752838A (zh) 制备引入外源抗原受体的细胞的方法
US20240368540A1 (en) Universal donor stem cells and related methods
EP3352798B1 (en) A method for high level and stable gene transfer in lymphocytes
JP6933898B2 (ja) 養子細胞治療製品を製造するための誘導多能性幹細胞の適用
US20190241910A1 (en) Genome edited immune effector cells
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
CA3182286A1 (en) Selection by essential-gene knock-in
CA3053499A1 (en) Donor repair templates multiplex genome editing
JP2017535284A (ja) 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
TW202342757A (zh) 經修飾副黏液病毒科附著醣蛋白
KR20230029659A (ko) 저면역원성 세포
TW202212352A (zh) 用於富集基因改造t細胞之方法
US20250333691A1 (en) Novel method
JP7807756B2 (ja) 所望の特異性を有するエフェクター細胞の製造方法
WO2024020587A2 (en) Pleiopluripotent stem cell programmable gene insertion
JP7681015B2 (ja) 同種ｔ細胞およびその産生方法
US20210238535A1 (en) Automated production of car-expressing cells
Xie et al. Plasmid-based electroporation for efficient genetic engineering in immortalized T lymphocytes
WO2006080248A1 (ja) 線状哺乳類人工染色体及びその構築方法
WO2021242989A1 (en) Compositions and methods for inducing cas9 protein expression by use of autonomous pd-1 promoter activity
KR20240069672A (ko) 대규모 염색체 전달 방법 및 이를 이용한 변형 염색체 및 유기체
HK40067933A (en) Allogeneic t-cells and methods for production thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination